BlackRock Amends Sarepta Stake, Maintains Passive Position
Ticker: SRPT · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 873303
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still owns a big chunk of Sarepta, signaling long-term confidence.**
AI Summary
BlackRock Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating its ownership of Sarepta Therapeutics Inc. common stock as of December 31, 2023. This amendment, the tenth for BlackRock regarding Sarepta, shows that BlackRock continues to hold a significant passive stake in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and its continued, albeit passive, holding suggests a long-term belief in Sarepta's value, which could be a positive signal for current or prospective shareholders.
Why It Matters
BlackRock's continued significant, passive ownership in Sarepta Therapeutics signals institutional confidence, which can reassure investors about the stock's long-term prospects.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate negative or highly volatile changes.
Analyst Insight
An investor should view this as a routine update from a major institutional holder. While it doesn't signal new buying or selling, BlackRock's continued passive stake suggests a stable, long-term institutional presence, which can be a minor positive for investor confidence in Sarepta Therapeutics.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Sarepta Therapeutics, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the date the SC 13G/A was filed
- Amendment No: 10 (number) — the number of amendments BlackRock has filed for Sarepta
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing under the Securities Exchange Act of 1934, specifically Amendment No: 10 for this particular holding.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., a major institutional investment management firm.
What company's stock is the subject of this filing?
The subject company whose common stock is being reported is Sarepta Therapeutics Inc.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Which rule under the Securities Exchange Act of 1934 is designated for this filing?
This Schedule 13G/A is filed pursuant to Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding Sarepta Therapeutics, Inc. (SRPT).